Abstract: Novel compounds of the general formula: and pharmaceutically acceptable acid addition salts thereof, wherein the compounds are useful in therapy to protect skeletal muscles against damage resulting from trauma or to protect skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, in the treatment of diabetes, in the treatment of cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction.
Type:
Grant
Filed:
December 5, 2002
Date of Patent:
February 1, 2005
Assignee:
CV Therapeutics, Inc.
Inventors:
Jeff Zablocki, Prabha Ibrahim, Kevin Shenk, Elfaith Elzein, Venkata Palle
Abstract: The present invention relates to novel ABC1 polypeptides and nucleic acid molecules encoding the same. The invention also relates to recombinant vectors, host cells, and compositions comprising ABC1 polynucleotides, as well as to methods for producing ABC1 polypeptides. The invention also relates to antibodies that bind specifically to ABC1 polypeptides. In addition, the invention relates to methods for increasing cholesterol efflux as well as to methods for increasing ABC1 expression and activity. The present invention further relates to methods for identifying compounds that modulate the expression of ABC1 and methods for detecting the comparative level of ABC1 polypeptides and polynucleotides in a mammalian subject. The present invention also provides kits and compositions suitable for screening compounds to determine the ABC1 expression modulating activity of the compound, as well as kits and compositions suitable to determine whether a compound modulates ABC1-dependent cholesterol efflux.
Type:
Application
Filed:
August 18, 2004
Publication date:
January 13, 2005
Applicant:
CV Therapeutics, Inc.
Inventors:
Richard Lawn, David Wade, Michael Garvin
Abstract: Disclosed are novel A2B adenosine receptor antagonists compounds having the structure of Formula I or Formula II:
The compounds are particularly useful for treating asthma, inflammatory gastrointestinal tract disorders, cardiovascular diseases, neurological disorders, and diseases related to undesirable angiogenesis.
Abstract: The present invention relates to novel ABC1 polypeptides and nucleic acid molecules encoding the same. The invention also relates to recombinant vectors, host cells, and compositions comprising ABC1 polynucleotides, as well as to methods for producing ABC1 polypeptides. The invention also relates to antibodies that bind specifically to ABC1 polypeptides. In addition, the invention relates to methods for increasing cholesterol efflux as well as to methods for increasing ABC1 expression and activity. The present invention further relates to methods for identifying compounds that modulate the expression of ABC1 and methods for detecting the comparative level of ABC1 polypeptides and polynucleotides in a mammalian subject. The present invention also provides kits and compositions suitable for screening compounds to determine the ABC1 expression modulating activity of the compound, as well as kits and compositions suitable to determine whether a compound modulates ABC1-dependent cholesterol efflux.
Type:
Grant
Filed:
June 16, 2000
Date of Patent:
November 23, 2004
Assignee:
CV Therapeutics, Inc.
Inventors:
Richard M. Lawn, David Wade, Michael Garvin
Abstract: 2-adenosine C-pyrazole compounds having formula (a) and methods for using the compounds as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.
Type:
Application
Filed:
March 30, 2004
Publication date:
October 7, 2004
Applicant:
CV Therapeutics, Inc.
Inventors:
Jeff A. Zablocki, Elfatih O. Elzein, Venkata P. Palle
Abstract: A compound having the formula:
wherein: R1 is —X—R1′; in which R1′ is lower alkyl, substituted lower alkyl, aryl, substituted aryl, heteroaryl, or substituted heteroaryl, or heterocyclic, and X is —NH—; R2 is isopropyl; and R3 is —NR4R5; in which R4 is hydrogen and R5 is lower alkyl substituted with amino or R4 and R5 are both lower alkyl substituted with one, two or three groups chosen from hydroxy and amino, or an acid addition salt or cationic salt thereof. The compounds inhibit CDK-2 activity and are useful for treating disorders characterized by undesirable cell proliferation.
Type:
Grant
Filed:
August 14, 2001
Date of Patent:
September 21, 2004
Assignee:
CV Therapeutics, Inc.
Inventors:
Robert T. Lum, Cheri Lynn Blum, Richard Mackman, Michael M. Wick, Steven R. Schow
Abstract: 2-adenosine C-pyrazole compounds having formula (a) and methods for using the compounds as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.
Type:
Grant
Filed:
March 12, 2002
Date of Patent:
August 3, 2004
Assignee:
CV Therapeutics, Inc.
Inventors:
Jeff A. Zablocki, Elfatih O. Elzein, Venkata P. Palle
Abstract: The present invention provides a method for identifying and using partial adenosine A2A receptor agonists that are useful as adjuncts in myocardiological perfusion imaging.
Type:
Application
Filed:
July 2, 2003
Publication date:
July 15, 2004
Applicant:
CV Therapeutics, Inc.
Inventors:
Luiz Belardinelli, Brent K. Blackburn, Zhenhai Gao
Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/nL.
Type:
Application
Filed:
July 7, 2003
Publication date:
February 12, 2004
Applicant:
CV Therapeutics, Inc.
Inventors:
Andrew A. Wolff, Fiona Baker, John Richard Langridge
Abstract: Methods are disclosed for treating congestive heart failure with partial inhibitors of fatty acid oxidation. The compounds increase cardiac performance without affecting heart rate, blood pressure, or oxygen consumption.
Type:
Grant
Filed:
August 27, 2002
Date of Patent:
January 13, 2004
Assignee:
CV Therapeutics, Inc.
Inventors:
Andrew A. Wolff, Brent Blackburn, Hani Naief Sabbah, William Clark Stanley
Abstract: Novel compounds of the general formula:
and pharmaceutically acceptable acid addition salts thereof, wherein the compounds are useful in therapy to protect skeletal muscles against damage resulting from trauma or to protect skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, in the treatment of cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction.
Type:
Grant
Filed:
February 22, 2001
Date of Patent:
January 13, 2004
Assignee:
CV Therapeutics, Inc.
Inventors:
Brent K. Blackburn, Jeff Zablocki, Elfatih Elzein, Grigory Nudelman
Abstract: Novel compounds of the general formula:
and pharmaceutically acceptable acid addition salts thereof, wherein the compounds are useful in therapy to protect skeletal muscles against damage resulting from trauma or to protect skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, in the treatment of cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction.
Type:
Grant
Filed:
February 22, 2001
Date of Patent:
January 13, 2004
Assignee:
CV Therapeutics, Inc.
Inventors:
Jeff Zablocki, Elfatih Elzein, Grigory Nudelman, Tim Marquart, Brent K. Blackburn, Venkata P. Palle
Abstract: N-pyrazole substituted 2-adenosine compounds and methods for using the compounds as A2A-adenosine receptor agonists useful to stimulate mammalian coronary vasodilation for therapeutic purposes and as adjuncts in cardiological imaging.
Type:
Grant
Filed:
April 12, 2002
Date of Patent:
November 4, 2003
Assignee:
CV Therapeutics, Inc.
Inventors:
Jeff A. Zablocki, Elfatih O. Elzein, Venkata P. Palle
Abstract: Novel compounds of the general formula:
and pharmaceutically acceptable acid addition salts thereof, wherein the compounds are useful in therapy to protect skeletal muscles against damage resulting from trauma or to protect skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, in the treatment of cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction.
Type:
Grant
Filed:
February 22, 2001
Date of Patent:
October 28, 2003
Assignee:
CV Therapeutics, Inc.
Inventors:
Elfaith Elzein, Jeff Zablocki, Tim Marquart
Abstract: A method and composition for inhibiting human cholesterol absorption comprising ingesting a therapeutic amount of an inhibitor of human cholesterol esterase comprising very high molecular weight sulfated polysaccharide having a sulfate to monomer ratio of from 1.0 to 3.0, containing less than about 5.0 wt. percent of sulfated polysaccharides having a molecular weight less than 75,000 Daltons, and containing less than 0.5 weight percent of inorganic sulfate.
Type:
Grant
Filed:
March 18, 1997
Date of Patent:
October 14, 2003
Assignee:
CV Therapeutics, Inc.
Inventors:
Louis G. Lange, III, Curtis A. Spilburg, Dayton T. Reardan
Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.
Type:
Grant
Filed:
September 27, 2002
Date of Patent:
September 16, 2003
Assignee:
CV Therapeutics, Inc.
Inventors:
Andrew A. Wolff, Fiona Baker, John Langridge
Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.